JPMorgan Lowers Novo Nordisk Rating After REDEFINE-4 Shows CagriSema Trailing Lilly’s Zepbound
JPMorgan moved Novo Nordisk to Neutral from Overweight and trimmed its price target to 250 Danish crowns from 350 after late-stage REDEFINE-4 data suggested CagriSema is less competitive than Eli Lilly’s Zepbound. The bank significantly reduced sales and earnings forecasts for Novo across the 2026-2030 period, and shares fell in Copenhagen trading.…